http://gsu.technologypublisher.comBe the first to know about the latest inventions and technologies available from Georgia State Universityen-USSat, 04 Apr 2026 22:50:48 GMTThu, 19 Mar 2026 07:54:18 GMThttp://blogs.law.harvard.edu/tech/rsspantherinnovations@gsu.eduCopyright 2026, Georgia State University2021-006https://gsu.technologypublisher.com/tech?title=Self-Adjuvanting%2c_Needle-Free_Nanoparticle_Vaccine_Platform_for_Next-Generation_Respiratory_VaccinesThu, 19 Mar 2026 07:54:18 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Self-Adjuvanting%2c_Needle-Free_Nanoparticle_Vaccine_Platform_for_Next-Generation_Respiratory_Vaccines2021-024https://gsu.technologypublisher.com/tech?title=Ultra-Compact%2c_Highly_Accurate_Color_SensorThu, 19 Mar 2026 07:50:18 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Ultra-Compact%2c_Highly_Accurate_Color_Sensor2025-003https://gsu.technologypublisher.com/tech?title=Highly-Sensitive_Point-of-Care_%0aDiagnostics_%2b_Disease_MonitoringTue, 28 Oct 2025 11:02:11 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Highly-Sensitive_Point-of-Care_%0aDiagnostics_%2b_Disease_Monitoring2022-018https://gsu.technologypublisher.com/tech/Targeted_Oral_Nanotherapy_for_IBD_Treatment_and_RecoveryDescription This technology is a lipid nanoparticle formulation composed of a proprietary blend of three major lipids identified in ginger-derived nanoparticles (GDNPs 2), isolated from edible ginger. These nanoparticles are orally administered, non-toxic, and selectively target the colon. Designed specifically for colon-specific delivery, these nanoparticles may treat inflammatory bowel disease (IBD) and other gastrointestinal disorders. This formulation has significantly suppressed colonic expression of key pro-inflammatory cytokines, accelerated intestinal wound healing, and prevented chro...Tue, 28 Oct 2025 10:48:26 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Targeted_Oral_Nanotherapy_for_IBD_Treatment_and_Recovery2017-15https://gsu.technologypublisher.com/tech/Next-Generation_Immunotherapy_to_Overcome_Tumor_ResistanceDescription This technology is a next-generation oncolytic virus (OV) designed to address the critical challenge of tumor resistance in cancer therapy. Built on the vesicular stomatitis virus (VSV) platform, this engineered OV is capable of inducing strong, tumor-selective cell death even in apoptosis-resistant cancers. In preclinical studies, this technology significantly reduced tumor volume in breast and pancreatic cancer models and showed promising results when combined with immune checkpoint inhibitors. By modifying the tumor microenvironment and promoting immune cell infiltration, this...Tue, 28 Oct 2025 10:39:29 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Next-Generation_Immunotherapy_to_Overcome_Tumor_Resistance2025-011https://gsu.technologypublisher.com/tech/Innovative_Small_Molecules_for_Safe_Weight_Loss_and_Lean_Muscle_Mass_PreservationDescription This technology is a class of small molecules designed to treat obesity and obesity-related metabolic dysfunctions, including type 2 diabetes. These molecules show significant weight loss in preclinical mouse models without suppressing appetite or reducing physical activity. Importantly, they preserve lean muscle mass while reducing fat, a critical factor in maintaining long-term metabolic health. Studies have also shown favorable toxicological profiles and enhanced beta-cell function in obese mice. Additionally, they can be conveniently formulated as tablets or capsules, making t...Tue, 28 Oct 2025 10:31:44 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Innovative_Small_Molecules_for_Safe_Weight_Loss_and_Lean_Muscle_Mass_Preservation2024-015https://gsu.technologypublisher.com/tech/High-Impact_Vaccine_Adjuvant_for_Influenza_and_BeyondTue, 28 Oct 2025 10:22:01 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/High-Impact_Vaccine_Adjuvant_for_Influenza_and_Beyond2019-16https://gsu.technologypublisher.com/tech?title=Single-Step%2c_Label-Free%2c_Highly_Accurate_Analyte_DetectionThu, 28 Aug 2025 12:32:15 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Single-Step%2c_Label-Free%2c_Highly_Accurate_Analyte_Detection2021-009https://gsu.technologypublisher.com/tech/Targeted_Therapy_for_Inflammatory_Diseases_and_CancerDescription This technology is a biologic therapy that modulates macrophage activity to redirect immune responses, reduces inflammation, and suppresses tumor growth. Preclinical studies in mouse models show that treatment with this technology significantly reduces tumor burden, decreases metastasis spread, and reshapes the tumor microenvironment. These findings support its potential as a promising therapeutic strategy for both cancer and inflammatory diseases. Cancer remains one of the most urgent global health challenges, with 20 million new cases and 9.7 million deaths reported worldwide i...Fri, 18 Jul 2025 07:40:32 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Targeted_Therapy_for_Inflammatory_Diseases_and_Cancer2025-019https://gsu.technologypublisher.com/tech/Highly_Effective_Monoclonal_Antibodies_for_Gonorrhea_TreatmentDescription This technology is a series of novel monoclonal antibodies (mAbs) developed to specifically block the growth of N. gonorrhoeae. In preclinical studies, select mAbs not only reduced clinical symptoms and bacterial load in mice but also conferred cross-protection against invasive Neisseria meningitidis (Nme) infection. These findings support the potential of the mAbs as both a targeted therapeutic and a broad-spectrum preventive strategy against Neisseria infections. Gonorrhea remains a major public health challenge, with approximately 1.5 million cases reported annually in the U.S...Fri, 18 Jul 2025 07:27:34 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Highly_Effective_Monoclonal_Antibodies_for_Gonorrhea_Treatment2025-014https://gsu.technologypublisher.com/tech/Smart_ROS-Triggered_Prodrug_Platform_for_Cancer_and_Infectious_Disease_TreatmentDescription This technology is a novel class of ROS (Reactive Oxygen Species)-sensitive linkers and related prodrugs designed for the targeted treatment of cancer and infectious diseases. This technology utilizes the elevated ROS levels present in diseased tissues to selectively activate therapeutic compounds, enabling precise drug release at the site of illness. Two anticancer agents, Floxuridine (Flox) and SN-38, have been successfully adapted into this prodrug system, demonstrating controlled stability and rapid activation in ROS-rich environments, such as cancer cells (e.g., HeLa cells). ...Fri, 18 Jul 2025 06:15:44 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Smart_ROS-Triggered_Prodrug_Platform_for_Cancer_and_Infectious_Disease_Treatment2017-05https://gsu.technologypublisher.com/tech?title=Egg-Free_Universal_Flu_Vaccine_for_Robust%2c_Long-Lasting_ImmunityDescription This technology is a nanoparticle-based influenza vaccine that provides broad and durable protection against both influenza A and B viruses. It elicits strong, long-lasting adaptive immunity and fully protects vaccinated animals from a wide range of influenza A strains, without the use of adjuvants. Designed for versatility, the vaccine can potentially be delivered via injection, nasal spray or drops, or self-administered microneedle patches. More than 3 million cases of influenza are reported in the US alone each year, resulting in high mortality and morbidity. Annual influenza ...Fri, 18 Jul 2025 05:53:48 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Egg-Free_Universal_Flu_Vaccine_for_Robust%2c_Long-Lasting_Immunity2025-005https://gsu.technologypublisher.com/tech/Powerful_Formulation_for_Respiratory_Infection_Prevention_and_TreatmentWed, 14 May 2025 08:51:29 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Powerful_Formulation_for_Respiratory_Infection_Prevention_and_Treatment2022-002https://gsu.technologypublisher.com/tech?title=Potent%2c_Safer_Respiratory_Syncytial_Virus_TherapeuticsWed, 14 May 2025 08:50:06 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Potent%2c_Safer_Respiratory_Syncytial_Virus_Therapeutics2021-008https://gsu.technologypublisher.com/tech/Highly_Selective_and_Sensitive_Carbon_Monoxide_ProbeTue, 08 Apr 2025 11:23:54 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Highly_Selective_and_Sensitive_Carbon_Monoxide_Probe2024-018https://gsu.technologypublisher.com/tech/Highly_Effective_Nanobodies_to_Treat_Henipavirus_InfectionsTue, 08 Apr 2025 11:15:46 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Highly_Effective_Nanobodies_to_Treat_Henipavirus_Infections2025-0017https://gsu.technologypublisher.com/tech?title=High-Performing%2c_Dual_Purpose%2c_Anti-Cancer_AgentsWed, 12 Mar 2025 04:55:29 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=High-Performing%2c_Dual_Purpose%2c_Anti-Cancer_Agents2024-006https://gsu.technologypublisher.com/tech/Hydrogen_Sulfide-Releasing_Therapeutics_Reduce_NSAID_Toxicity_and_Provide_Protection_During_StrokeDescription This technology is a suite of hydrogen sulfide (H2S) prodrugs that has broad applicability for decreasing toxicity during the treatment of inflammation using NSAIDs. In vivo studies have demonstrated reduction of gastrointestinal ulcers, kidney toxicity, and liver toxicity during NSAID use. In separate in vivo studies, these technologies reduced brain tissue damage in ischemic stroke. These H2S prodrugs release H2S in response to biologically relevant triggers. In contrast to H2S prodrugs in development, these technologies offer controlled, tunable release and improved biocompatib...Fri, 21 Feb 2025 12:57:15 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Hydrogen_Sulfide-Releasing_Therapeutics_Reduce_NSAID_Toxicity_and_Provide_Protection_During_Stroke2023-030https://gsu.technologypublisher.com/tech?title=Faster%2c_More_Accurate%2c_Mouse_Behavior_Tracking_ToolFri, 21 Feb 2025 07:45:37 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Faster%2c_More_Accurate%2c_Mouse_Behavior_Tracking_Tool2017-18https://gsu.technologypublisher.com/tech/Glycan_Binding_HTS_Platform_for_Drug_DevelopmentFri, 21 Feb 2025 07:38:35 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Glycan_Binding_HTS_Platform_for_Drug_Development2014-07https://gsu.technologypublisher.com/tech/Anti-Biofilm_Agent_Effective_At_Low_DosesFri, 21 Feb 2025 07:26:22 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Anti-Biofilm_Agent_Effective_At_Low_Doses2020-006https://gsu.technologypublisher.com/tech/Highly_Effective_Therapeutics_to_Overcome_Antibiotic_ResistanceFri, 21 Feb 2025 07:21:02 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Highly_Effective_Therapeutics_to_Overcome_Antibiotic_Resistance2011-10https://gsu.technologypublisher.com/tech/Selective_Chemotherapeutics_That_Specifically_Target_Tumor_CellsFri, 21 Feb 2025 07:12:55 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Selective_Chemotherapeutics_That_Specifically_Target_Tumor_Cells2024-002https://gsu.technologypublisher.com/tech/Highly_Specific_Cartilage-Targeting_Imaging_Agents_for_Early_Detection_of_ArthritisFri, 21 Feb 2025 07:01:44 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Highly_Specific_Cartilage-Targeting_Imaging_Agents_for_Early_Detection_of_Arthritis2018-18https://gsu.technologypublisher.com/tech?title=Safe%2c_Effective_Biofilm_Inhibition_Without_Increasing_Antimicrobial_ResistanceThu, 20 Feb 2025 11:15:31 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Safe%2c_Effective_Biofilm_Inhibition_Without_Increasing_Antimicrobial_Resistance2022-001https://gsu.technologypublisher.com/tech/Simple_Graphene_Coating_Process_for_High_Performance_Device_Fabrication_Without_ContaminationThu, 20 Feb 2025 09:15:24 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Simple_Graphene_Coating_Process_for_High_Performance_Device_Fabrication_Without_Contamination2018-25https://gsu.technologypublisher.com/tech?title=Low_Energy_Photosensitizers_with_Improved_Safety_and_Efficacy_for_Dermatological_Conditions%0aDescriptionThu, 23 Jan 2025 07:35:25 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Low_Energy_Photosensitizers_with_Improved_Safety_and_Efficacy_for_Dermatological_Conditions%0aDescription2017-24https://gsu.technologypublisher.com/tech?title=Non-Invasive%2c_Early-Stage_Liver_Fibrosis_DiagnosticDescription This technology is a cutting-edge non-invasive liver fibrosis detection technology, a revolutionary advancement in the early diagnosis of liver fibrosis. Detecting liver fibrosis early is crucial because it helps address and potentially prevent the progression of liver diseases that can lead to more severe conditions such as cirrhosis, liver failure, or liver cancer. This technology interprets data from Doppler ultrasound scans to accurately detect and stage liver fibrosis. Unlike traditional methods, which are often invasive, unreliable, and expensive, our solution offers a safer...Mon, 04 Nov 2024 08:03:58 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Non-Invasive%2c_Early-Stage_Liver_Fibrosis_Diagnostic2016-03https://gsu.technologypublisher.com/tech/Safer_Canine_Distemper_Virus_VaccineMon, 04 Nov 2024 07:56:51 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Safer_Canine_Distemper_Virus_Vaccine2024-005https://gsu.technologypublisher.com/tech?title=Highly_Effective%2c_Tunable%2c_Intracellular_CO_TherapeuticsWed, 28 Aug 2024 07:16:12 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Highly_Effective%2c_Tunable%2c_Intracellular_CO_Therapeutics2023-031https://gsu.technologypublisher.com/tech/Highly_Sensitive_RSV_Reporter_Tools_for_Anti-Viral_Drug_DiscoveryWed, 28 Aug 2024 07:16:09 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Highly_Sensitive_RSV_Reporter_Tools_for_Anti-Viral_Drug_Discovery2023-014https://gsu.technologypublisher.com/tech?title=Highly_Effective%2c_Patient-Specific_Neuromodulation_TherapyDescription This technology is a novel personalized neuromodulation therapy. There are more than 600 neurological disorders affecting patients and they impact an estimated 50 million patients each year in the US alone. In recent years, deep brain stimulation (DBS), which uses the focused delivery of current to the brain to affect neural processes, has been used as a treatment for nervous system disorders. However, the outcome of the DBS varies from patient to patient and is not predictable. Scientists at Georgia State have developed a novel machine learning process that can accurately link th...Wed, 28 Aug 2024 07:16:04 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Highly_Effective%2c_Patient-Specific_Neuromodulation_Therapy2023-010https://gsu.technologypublisher.com/tech/Stop_Sexual_Assault_On_College_Campuses!Description This technology is a web-based alcohol and sexual assault prevention program with tailored content based on gender and sexual orientation. It is estimated that 25 percent of American women have experienced sexual assault. Approximately 50% of those cases involve alcohol consumption by the perpetrator, victim, or both. Sexual assault is common among college students. This web-based program targets alcohol use and sexual assault victimization, perpetration, and bystander intervention in a single program. More importantly, it tailored feedback for all men, women, and LGBTQ+ students,...Wed, 28 Aug 2024 07:16:02 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Stop_Sexual_Assault_On_College_Campuses!2023-004https://gsu.technologypublisher.com/tech?title=Highly_Immunogenic%2c_Universal_COVID-19_VaccineWed, 28 Aug 2024 07:16:00 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech?title=Highly_Immunogenic%2c_Universal_COVID-19_Vaccine2023-002https://gsu.technologypublisher.com/tech/Highly_Effective_T_Cell-Exclusive_COVID_VaccineWed, 28 Aug 2024 07:15:58 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Highly_Effective_T_Cell-Exclusive_COVID_Vaccine2022-030https://gsu.technologypublisher.com/tech/Novel_Covid_Anti-Viral_TherapeuticsWed, 28 Aug 2024 07:15:56 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Novel_Covid_Anti-Viral_Therapeutics2022-027https://gsu.technologypublisher.com/tech/Highly_Effective_Therapeutics_for_Acute_Lymphocytic_LeukemiaDescription This technology is a series of small molecule inhibitors designed to treat Acute Lymphocytic Leukemia (ALL), a rapidly progressing cancer affecting lymphoid blood cells and bone marrow. The disease progresses rapidly and creates immature blood cells rather than mature ones. The leukemia cells are carried in the bloodstream to other organs and tissues where they continue to grow and divide, spreading to different organs. There is a need for effective treatment options for ALL as outcomes for patients (who went through chemotherapy) remain suboptimal. The 5-year overall survival is ...Wed, 28 Aug 2024 07:15:55 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Highly_Effective_Therapeutics_for_Acute_Lymphocytic_Leukemia2021-017https://gsu.technologypublisher.com/tech/Deep_Tissue_Imaging_Agents_With_Improved_Tumor-Killing_CapabilitiesWed, 28 Aug 2024 07:15:46 GMTpantherinnovations@gsu.eduhttps://gsu.technologypublisher.com/tech/Deep_Tissue_Imaging_Agents_With_Improved_Tumor-Killing_Capabilities